Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1359 ARTÍCULOS , VIENDO DEL 421 AL 435

Pharmacological treatment of Alzheimer disease

Massoud F, Léger GC.

Can J Psychiatry. 2011 Oct;56(10):579-88. doi: 10.1177/070674371105601003.

Nonpharmacological treatment of Alzheimer disease

Ballard C, Khan Z, Clack H, Corbett A.

Can J Psychiatry. 2011 Oct;56(10):589-95. doi: 10.1177/070674371105601004.

Effectiveness of interventions to prevent falls in people with Alzheimer's disease and related dementias

Jensen LE, Padilla R.

Am J Occup Ther. 2011 Sep-Oct;65(5):532-40. doi: 10.5014/ajot.2011.002626.

Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease

Miller BW, Willett KC, Desilets AR.

Ann Pharmacother. 2011 Nov;45(11):1416-24. doi: 10.1345/aph.1Q238. Epub 2011 Oct 25.

Neuropathologic features associated with Alzheimer disease diagnosis: age matters

Middleton LE, Grinberg LT, Miller B, Kawas C, Yaffe K.

Neurology. 2011 Nov 8;77(19):1737-44. doi: 10.1212/WNL.0b013e318236f0cf. Epub 2011 Oct 26.

[Alzheimer: destiny of a disease]

Deleuze J.

Rev Prat. 2011 Sep;61(7):891.

Hybrid-based multi-target ligands for the treatment of Alzheimer's disease

Rampa A, Belluti F, Gobbi S, Bisi A.

Curr Top Med Chem. 2011 Nov;11(22):2716-30. doi: 10.2174/156802611798184409.

Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease

Bolognesi ML, Simoni E, Rosini M, Minarini A, Tumiatti V, Melchiorre C.

Curr Top Med Chem. 2011 Nov;11(22):2797-806. doi: 10.2174/156802611798184373.

1,8-Naphthyridine derivatives as cholinesterases inhibitors and cell Ca2+ regulators, a multitarget strategy for Alzheimer's disease

Egea J, de los Rios C.

Curr Top Med Chem. 2011 Nov;11(22):2807-23. doi: 10.2174/156802611798184418.

Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders

Zlokovic BV.

Nat Rev Neurosci. 2011 Nov 3;12(12):723-38. doi: 10.1038/nrn3114.

Multi-target-directed ligands in Alzheimer's disease treatment

Bajda M, Guzior N, Ignasik M, Malawska B.

Curr Med Chem. 2011;18(32):4949-75. doi: 10.2174/092986711797535245.

Challenges associated with curcumin therapy in Alzheimer disease

Belkacemi A, Doggui S, Dao L, Ramassamy C.

Expert Rev Mol Med. 2011 Nov 4;13:e34. doi: 10.1017/S1462399411002055.

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type

Dhillon S.

Drugs Aging. 2011 Nov 1;28(11):927-30. doi: 10.2165/11207090-000000000-00000.

Prospects for designating Alzheimer's disease research a national priority

Khachaturian ZS.

Alzheimers Dement. 2011 Nov;7(6):557-61. doi: 10.1016/j.jalz.2011.10.001.

Presenilin enhancer-2 gene: identification of a novel promoter mutation in a patient with early-onset familial Alzheimer's disease

Andreoli V, Trecroci F, La Russa A, Cittadella R, Liguori M, Spadafora P, Caracciolo M, Di Palma G, Colica C, Gambardella A, Quattrone A.

Alzheimers Dement. 2011 Nov;7(6):574-8. doi: 10.1016/j.jalz.2011.02.010.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias